Cell-free DNA Analysis of Spent Embryo Culture Media as a Non-invasive Approach for Preimplantation Genetic Diagnosis
NCT ID: NCT07076719
Last Updated: 2025-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2023-10-01
2024-08-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To collect SCM from blastocysts of good quality obtained from IVF cycles.
2. To extract cfDNA from the collected SCM using a commercially available kit.
3. To assess the chromosomal content in both cfDNA and gDNA samples via array-based comparative genomic hybridization (aCGH).
4. To compare the results obtained using cfDNA analysis to those obtained using conventional invasive PGD methods, such as blastomere biopsy.
5. To evaluate the potential advantages of using cfDNA analysis of spent embryo culture media for PGD, including reduced risk of harm to the embryo, reduced cost, and increased efficiency.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Isolation of Cell Free Fetal DNA From Spent Culture Medium and Its Potential Role for Preimplantation Genetic Diagnosis (PGD).
NCT06084377
Non-invasive Preimplantation Genetic Testing for Aneuploidies Using Cell-free DNA in Spent Culture Media
NCT04711239
Utilizing Free DNA in Embryo Culture for PGT
NCT02884063
Cell Free Preimplantation Genetic Testing
NCT04628507
Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)
NCT00702273
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Study Design
* Type of Study: This is a retrospective study.
* Location: The study was conducted at the Assisted Reproductive Technology Unit Life Zena Center, Baghdad, Baghdad Governorate, Iraq.
* Duration: The study was conducted from October 2023 to August 2024.
* Patient Criteria:
* Included: All patients referred for PGT-A.
* Excluded: Patients who had no blastocyst for biopsy were excluded.
* Ethical Approval: The study was approved by the Committee for the Scientific Research Ethics of Sohag University (CSRE-16-24).
2. Ovarian Stimulation and Oocyte Retrieval
• Protocols: Patients underwent controlled ovarian stimulation using either:
o A long down-regulation protocol with buserelin nasal spray (Suprecur, Hoechst, Germany) (Ravhon et al., 2000).
A short protocol incorporating a gonadotropin-releasing hormone (GnRH) antagonist (Cetrotide, Merck Serono, Germany) (Hohmann et al., 2003).
* Gonadotropin Administration: Daily administration included highly purified human menopausal gonadotropin (Menopur, Ferring, USA) or recombinant FSH (rFSH; Gonal-F, Serono, Switzerland, or Puregon, MSD, USA). Doses ranged from 150 to 450 IU (Bosch et al., 2024).
* Ovulation Trigger: Ovulation was triggered when at least three follicles reached ≥18 mm in diameter. The trigger agents used were either 5,000 IU of hCG (Pregnyl, MSD, USA) or 0.2 mg triptorelin (Decapeptyl, Ferring, Sweden) (Schachter et al., 2008)).
* Oocyte Retrieval: Transvaginal oocyte retrieval was performed 36 hours post-trigger, followed by intracytoplasmic sperm injection (ICSI).
3. Fertilization and Embryo Culture
* Oocyte Preparation: Collected oocytes were denuded using hyaluronidase (Ref. 10017, Vitrolife, Goteborg, Sweden). They were then incubated for a minimum of one hour before insemination.
* Insemination: Oocytes were inseminated via ICSI after 4-6 hours of recovery.
* Initial Culture: Fertilized oocytes were cultured in G-1 medium (Ref. 10127, Vitrolife, Goteborg, Sweden) supplemented with 10% serum substitute supplement (SSS; Ref. 99193, Irvine Scientific, USA).
* Day 3 Processing: On day 3 of development, each embryo was gently washed and rinsed using a 200 µm pipette (K-FPIP-1170-10, Cook Medical, USA). A \~10 µm hole was drilled in the zona pellucida using a non-contact laser (Saturn 5 Active Laser System, Research Instrument, UK) (Desai et al., 2020).
* Blastocyst Culture: Embryos were then cultured individually to the blastocyst stage in G-2 medium (Ref. 10131, Vitrolife, Goteborg, Sweden) with 10% SSS.
* Culture Conditions: The sequential culture was carried out in 30 µl microdrops of media under oil (Ref. 10029, Vitrolife, Goteborg, Sweden). Incubation was performed at 37.0°C in a gas environment of 5% CO₂ and 5% O₂ balanced with N₂ (Zeng et al., 2024).
4. Trophectoderm (TE) Biopsy
* Blastocyst Grading: Blastocyst grading was based on criteria that classified embryos as good, fair, or poor using the simplified SART embryo scoring system (Heitmann et al., 2013):
* Good: AA or AB.
* Fair: BA, BB, BC.
* Poor: CB or CC.
* Biopsy Criteria: TE biopsy was performed when an embryo had at least one grade B or better for either the ICM or TE on day 5 of development. When no good-quality blastocysts were available in the same cohort, CC grade blastocysts were biopsied.
* Biopsy Procedure: 5-8 cells were laser-biopsied from the TE. These cells were then rinsed and tubed for PGT.
* Cryopreservation: The biopsied embryo was cryopreserved by vitrification (Ref. 90133, Vit Kit-Freeze, Irvine Scientific, Santa Ana, USA) (Richardson et al., 2015).
5. Sample Collection and Processing
* DNA Contamination Minimization:
* Embryos and culture media were managed under stringent sterile conditions.
* Laboratory personnel received comprehensive training in embryo handling protocols and consistently utilized personal protective equipment (masks, caps, gloves).
* All laboratory materials and equipment were exclusively dedicated to the study to prevent cross-contamination.
* Meticulous removal of surrounding cumulus cells was performed prior to microinjection in ICSI cycles or at the time of fertilization in conventional IVF cycles to reduce maternal DNA contamination.
* These practices align with established guidelines for good laboratory practices in IVF settings (Krasic et al., 2021).
* Sample Collection: Paired samples were obtained from 50 embryos that had reached the Day-5 blastocyst stage. From each embryo, we collected the SCM in which it was developing. Subsequently, a corresponding biopsy of the TE was performed and the tissue was collected. All embryos were sourced from a cohort of 20 patients.
* SCM was harvested after embryo culture with care taken not to include cellular material.
* TE biopsies were performed according to standard protocols under strict aseptic conditions.
* Sample Storage: Samples were stored immediately at -80°C until further processing to prevent degradation of DNA.
* Processing for Genetic Analysis: TE samples were processed directly for genetic analysis (Magli et al., 2008).
6. DNA Extraction and Sample Preparation
* cfDNA Extraction: cfDNA was extracted from SCM using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany). This kit includes a centrifugation step, protein digestion, and silica membrane-based DNA binding optimized for low-yield samples.
* gDNA Extraction: Genomic DNA (gDNA) was concurrently isolated from the TE biopsy samples using the DNeasy Blood and Tissue Kit (Qiagen), following the manufacturer's instructions (Rubio et al., 2020).
7. Microarray Comparative Genomic Hybridization (aCGH)
* Chromosomal Assessment: Chromosomal content was assessed in both cfDNA and gDNA samples via array-based comparative genomic hybridization (aCGH).
* BAC-chip Slides: MACArray Karyo 1440 BAC-chip slides were employed to enable high-resolution, whole-genome profiling.
* Labeling and Hybridization:
* Extracted DNA was fluorescently labeled: cfDNA with Cy3 (green) and TE DNA with Cy5 (red).
* Labeled DNA was hybridized onto oligonucleotide microarrays containing probes across all 23 chromosomes (Mertzanidou et al., 2013).
* Scanning and Data Acquisition:
* Post-hybridization, arrays were scanned using an Agilent SureScan microarray scanner (Agilent Technologies, Santa Clara, USA).
* Signal intensities were quantified, and log₂ ratios of Cy3 to Cy5 fluorescence were calculated to identify chromosomal gains and losses.
* Data Processing and Analysis:
* Chromosomal imbalances were analyzed using Agilent CytoGenomics and Genomic Workbench v7.0.4.0 software.
* Signal data were converted into log₁₀ ratios to determine DNA copy number variations (CNVs).
* Statistical thresholds were applied to minimize false positives and negatives, regarding established concordance frameworks (Yatsenko et al., 2009).
8. Validation and Quality Control
• Robust quality control measures included:
* Negative controls during DNA extraction to detect contamination.
* Evaluation of hybridization efficiency via reference DNA consistency.
* Exclusion of results with poor signal-to-noise ratios (Rubio et al., 2019).
9. Statistical Analysis
* Comparison of Profiles: Chromosomal profiles of cfDNA and TE samples were compared using Chi-square tests.
* Statistical Significance: P-values \<0.05 were considered statistically significant.
10. Software Tools
* Statistical Analyses: All statistical analyses were performed using SPSS.
* Visual Data Representations: Visual data representations were generated using GraphPad Prism.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Patients underwent controlled ovarian stimulation using either:
o A long down-regulation protocol with buserelin nasal spray (Suprecur, Hoechst, Germany).
A short protocol incorporating a gonadotropin-releasing hormone (GnRH) antagonist.
* Gonadotropin Administration: Daily administration included highly purified human menopausal gonadotropin or recombinant FSH. Doses ranged from 150 to 450 IU.
* Ovulation Trigger: Ovulation was triggered when at least three follicles reached ≥18 mm in diameter. The trigger agents used were either 5,000 IU of hCG or 0.2 mg triptorelin).
* Oocyte Retrieval: Transvaginal oocyte retrieval was performed 36 hours post-trigger, followed by intracytoplasmic sperm injection (ICSI).
3\. Fertilization and Embryo Culture 4. Trophectoderm (TE) Biopsy 5. Sample Collection and Processing
Trophectoderm (TE) Biopsy
* Blastocyst Grading: Blastocyst grading was based on criteria that classified embryos as good, fair, or poor using the simplified SART embryo scoring system (Heitmann et al., 2013):
* Good: AA or AB.
* Fair: BA, BB, BC.
* Poor: CB or CC.
* Biopsy Criteria: TE biopsy was performed when an embryo had at least one grade B or better for either the ICM or TE on day 5 of development. When no good-quality blastocysts were available in the same cohort, CC grade blastocysts were biopsied.
* Biopsy Procedure: 5-8 cells were laser-biopsied from the TE. These cells were then rinsed and tubed for PGT.
* Cryopreservation: The biopsied embryo was cryopreserved by vitrification (Ref. 90133, Vit Kit-Freeze, Irvine Scientific, Santa Ana, USA) (Richardson et al., 2015).
Non-invasive Preimplantation Genetic Diagnosis
* DNA Contamination Minimization:
o SCM was harvested after embryo culture with care taken not to include cellular material.
* Sample Storage:
* Processing for Genetic Analysis:
6\. DNA Extraction and Sample Preparation 7. Microarray Comparative Genomic Hybridization (aCGH)
* Chromosomal Assessment:
* BAC-chip Slides:
* Labeling and Hybridization:
* Scanning and Data Acquisition:
* Data Processing and Analysis:
8\. Validation and Quality Control
* Robust quality control measures included:
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trophectoderm (TE) Biopsy
* Blastocyst Grading: Blastocyst grading was based on criteria that classified embryos as good, fair, or poor using the simplified SART embryo scoring system (Heitmann et al., 2013):
* Good: AA or AB.
* Fair: BA, BB, BC.
* Poor: CB or CC.
* Biopsy Criteria: TE biopsy was performed when an embryo had at least one grade B or better for either the ICM or TE on day 5 of development. When no good-quality blastocysts were available in the same cohort, CC grade blastocysts were biopsied.
* Biopsy Procedure: 5-8 cells were laser-biopsied from the TE. These cells were then rinsed and tubed for PGT.
* Cryopreservation: The biopsied embryo was cryopreserved by vitrification (Ref. 90133, Vit Kit-Freeze, Irvine Scientific, Santa Ana, USA) (Richardson et al., 2015).
Non-invasive Preimplantation Genetic Diagnosis
* DNA Contamination Minimization:
o SCM was harvested after embryo culture with care taken not to include cellular material.
* Sample Storage:
* Processing for Genetic Analysis:
6\. DNA Extraction and Sample Preparation 7. Microarray Comparative Genomic Hybridization (aCGH)
* Chromosomal Assessment:
* BAC-chip Slides:
* Labeling and Hybridization:
* Scanning and Data Acquisition:
* Data Processing and Analysis:
8\. Validation and Quality Control
* Robust quality control measures included:
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assisted Reproductive Technology Unit Life Zena Center, Baghdad, Baghdad Governorate, Iraq
UNKNOWN
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hatem Awaga
Assistant Professor of Obstetrics and Gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Unit Life Zena Center
Baghdad, Baghdad Governorate, Iraq
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rubio C, Rienzi L, Navarro-Sanchez L, Cimadomo D, Garcia-Pascual CM, Albricci L, Soscia D, Valbuena D, Capalbo A, Ubaldi F, Simon C. Embryonic cell-free DNA versus trophectoderm biopsy for aneuploidy testing: concordance rate and clinical implications. Fertil Steril. 2019 Sep;112(3):510-519. doi: 10.1016/j.fertnstert.2019.04.038. Epub 2019 Jun 11.
Yatsenko SA, Shaw CA, Ou Z, Pursley AN, Patel A, Bi W, Cheung SW, Lupski JR, Chinault AC, Beaudet AL. Microarray-based comparative genomic hybridization using sex-matched reference DNA provides greater sensitivity for detection of sex chromosome imbalances than array-comparative genomic hybridization with sex-mismatched reference DNA. J Mol Diagn. 2009 May;11(3):226-37. doi: 10.2353/jmoldx.2009.080064. Epub 2009 Mar 26.
Mertzanidou A, Wilton L, Cheng J, Spits C, Vanneste E, Moreau Y, Vermeesch JR, Sermon K. Microarray analysis reveals abnormal chromosomal complements in over 70% of 14 normally developing human embryos. Hum Reprod. 2013 Jan;28(1):256-64. doi: 10.1093/humrep/des362. Epub 2012 Oct 9.
Rubio C, Navarro-Sanchez L, Garcia-Pascual CM, Ocali O, Cimadomo D, Venier W, Barroso G, Kopcow L, Bahceci M, Kulmann MIR, Lopez L, De la Fuente E, Navarro R, Valbuena D, Sakkas D, Rienzi L, Simon C. Multicenter prospective study of concordance between embryonic cell-free DNA and trophectoderm biopsies from 1301 human blastocysts. Am J Obstet Gynecol. 2020 Nov;223(5):751.e1-751.e13. doi: 10.1016/j.ajog.2020.04.035. Epub 2020 May 26.
Magli MC, Van den Abbeel E, Lundin K, Royere D, Van der Elst J, Gianaroli L; Committee of the Special Interest Group on Embryology. Revised guidelines for good practice in IVF laboratories. Hum Reprod. 2008 Jun;23(6):1253-62. doi: 10.1093/humrep/den068. Epub 2008 Mar 28.
Krasic J, Abramovic I, Vrtaric A, Nikolac Gabaj N, Kralik-Oguic S, Katusic Bojanac A, Jezek D, Sincic N. Impact of Preanalytical and Analytical Methods on Cell-Free DNA Diagnostics. Front Cell Dev Biol. 2021 Sep 6;9:686149. doi: 10.3389/fcell.2021.686149. eCollection 2021.
Zeng W, Xiao D, Chen R, Lu Y, Liang W, Sun H. A novel method for gas mixing and distribution in multi-chamber embryo incubators. Technol Health Care. 2024;32(S1):169-181. doi: 10.3233/THC-248015.
Schachter M, Friedler S, Ron-El R, Zimmerman AL, Strassburger D, Bern O, Raziel A. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertil Steril. 2008 Oct;90(4):1087-93. doi: 10.1016/j.fertnstert.2007.07.1316. Epub 2007 Nov 26.
Bosch E, Alama P, Romero JL, Mari M, Labarta E, Pellicer A. Serum progesterone is lower in ovarian stimulation with highly purified HMG compared to recombinant FSH owing to a different regulation of follicular steroidogenesis: a randomized controlled trial. Hum Reprod. 2024 Feb 1;39(2):393-402. doi: 10.1093/humrep/dead251.
Ravhon A, Aurell R, Lawrie H, Margara R, Winston RM. The significance of delayed suppression using buserelin acetate and recombinant follicle-stimulating hormone in a long protocol in vitro fertilization program. Fertil Steril. 2000 Feb;73(2):325-9. doi: 10.1016/s0015-0282(99)00521-x.
Yu, Y., Liang, X., Wang, W., et al. (2017). Whole-genome sequencing reveals multiple genetic alterations in mesonephric-like adenocarcinomas of the female genital tract. Gynecologic Oncology, 147(3), 617-625.
Xiong, B., Ma, H., Zhang, F., Li, Y., Zhou, C., Huang, L., Zhang, Y., Li, R., Wei, J., Liu, P., Wang, J., Tang, F., Liu, Z., Gao, F., & Li, J. (2012). A comparison of human embryo genome-wide copy number profiles was obtained using two different microarray platforms. Reproductive BioMedicine Online, 25(2), 155-161.
Wong CC, Loewke KE, Bossert NL, Behr B, De Jonge CJ, Baer TM, Reijo Pera RA. Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage. Nat Biotechnol. 2010 Oct;28(10):1115-21. doi: 10.1038/nbt.1686. Epub 2010 Oct 3.
Wang, Y., Cheng, Q., Meng, L., et al. (2017). Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies in patients with hepatocellular carcinoma. Oncotarget, 8(33), 54707.
Wang, Y., Chen, Y., Zhang, J., Liang, X., Xu, J., Wang, W., Zhang, X., Li, J., Jin, L., & Li, Z. (2018). Whole-genome sequencing of human preimplantation embryos reveals genetic abnormalities and embryonic development. Cell Research, 28(10), 973-987.
Wang, L., Zhang, J., Duan, J., et al. (2019). Assessment of human embryos by RNA sequencing, whole-exome sequencing, and karyomapping. Molecular Genetics & Genomic Medicine, 7(7), e00715.
Verlinsky, Y., Rechitsky, S., Verlinsky, O., et al. (2013). Preimplantation genetic diagnosis using polar bodies and blastomeres of cleavage stage embryos. Molecular and Cellular Endocrinology, 15(6), 334-339.
Vassena R, Boue S, Gonzalez-Roca E, Aran B, Auer H, Veiga A, Izpisua Belmonte JC. Waves of early transcriptional activation and pluripotency program initiation during human preimplantation development. Development. 2011 Sep;138(17):3699-709. doi: 10.1242/dev.064741. Epub 2011 Jul 20.
Scott RT Jr, Upham KM, Forman EJ, Hong KH, Scott KL, Taylor D, Tao X, Treff NR. Blastocyst biopsy with comprehensive chromosome screening and fresh embryo transfer significantly increases in vitro fertilization implantation and delivery rates: a randomized controlled trial. Fertil Steril. 2013 Sep;100(3):697-703. doi: 10.1016/j.fertnstert.2013.04.035. Epub 2013 Jun 1.
Scott RT Jr, Upham KM, Forman EJ, Zhao T, Treff NR. Cleavage-stage biopsy significantly impairs human embryonic implantation potential while blastocyst biopsy does not: a randomized and paired clinical trial. Fertil Steril. 2013 Sep;100(3):624-30. doi: 10.1016/j.fertnstert.2013.04.039. Epub 2013 Jun 15.
Parker, M. T., Knopf, C.W., & Sargent, L. (2007). A comparison of three methods for the estimation of DNA concentration and purity in calf thymus and human leukocytes. Analytical Biochemistry, 361(2), 249-251.
Mirkovic J, McFarland M, Garcia E, Sholl LM, Lindeman N, MacConaill L, Dong F, Hirsch M, Nucci MR, Quick CM, Crum CP, McCluggage WG, Howitt BE. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract. Am J Surg Pathol. 2018 Feb;42(2):227-233. doi: 10.1097/PAS.0000000000000958.
Kirkegaard K, Kesmodel US, Hindkjaer JJ, Ingerslev HJ. Time-lapse parameters as predictors of blastocyst development and pregnancy outcome in embryos from good prognosis patients: a prospective cohort study. Hum Reprod. 2013 Oct;28(10):2643-51. doi: 10.1093/humrep/det300. Epub 2013 Jul 30.
Handyside AH, Kontogianni EH, Hardy K, Winston RM. Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. Nature. 1990 Apr 19;344(6268):768-70. doi: 10.1038/344768a0.
Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2000 Jun;73(6):1155-8. doi: 10.1016/s0015-0282(00)00518-5.
Fragouli E, Lenzi M, Ross R, Katz-Jaffe M, Schoolcraft WB, Wells D. Comprehensive molecular cytogenetic analysis of the human blastocyst stage. Hum Reprod. 2008 Nov;23(11):2596-608. doi: 10.1093/humrep/den287. Epub 2008 Jul 29.
Fiorentino F, Bono S, Biricik A, Nuccitelli A, Cotroneo E, Cottone G, Kokocinski F, Michel CE, Minasi MG, Greco E. Application of next-generation sequencing technology for comprehensive aneuploidy screening of blastocysts in clinical preimplantation genetic screening cycles. Hum Reprod. 2014 Dec;29(12):2802-13. doi: 10.1093/humrep/deu277. Epub 2014 Oct 21.
Fiorentino F, Biricik A, Bono S, Spizzichino L, Cotroneo E, Cottone G, Kokocinski F, Michel CE. Development and validation of a next-generation sequencing-based protocol for 24-chromosome aneuploidy screening of embryos. Fertil Steril. 2014 May;101(5):1375-82. doi: 10.1016/j.fertnstert.2014.01.051. Epub 2014 Mar 6.
Zhang P, Zucchelli M, Bruce S, Hambiliki F, Stavreus-Evers A, Levkov L, Skottman H, Kerkela E, Kere J, Hovatta O. Transcriptome profiling of human pre-implantation development. PLoS One. 2009 Nov 16;4(11):e7844. doi: 10.1371/journal.pone.0007844.
Chen AA, Tan L, Suraj V, Reijo Pera R, Shen S. Biomarkers identified with time-lapse imaging: discovery, validation, and practical application. Fertil Steril. 2013 Mar 15;99(4):1035-43. doi: 10.1016/j.fertnstert.2013.01.143.
Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, Siu SS, Chan WC, Chan SL, Chan AT, Lai PB, Chiu RW, Lo YM. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem. 2013 Jan;59(1):211-24. doi: 10.1373/clinchem.2012.196014. Epub 2012 Oct 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSRE-16-24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.